Back to top

Eledon’s BESTOW Trial Completion: What Tegoprubart Could Mean for Transplant Investing

Eledon Pharmaceuticals, Inc. ($ELDN) announced an update on their ongoing clinical study. The Phase 2 BESTOW study, officially titled “AT-1501-K207...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Eledon Pharmaceuticals, Inc. (ELDN)